bharat biotech
- Hyderabad
DCGI permits Bharat Biotech to conduct trials for intranasal booster dose
New Delhi: In a major development on Friday, the Drugs Controller General of India (DCGI) allowed Hyderabad-based vaccine manufacturer Bharat Biotech to conduct clinical trials for its intranasal Covid booster dose in…
- Hyderabad
Hyderabad couple behind India’s Covid vaccine gets Padma Bhushan
Hyderabad: Dr Krishna Ella and Suchitra Ella, the couple behind Bharat Biotech, which developed India’s first indigenous vaccine for Covid-19, have been awarded Padma Bhushan, the third highest civilian award in the…
- Hyderabad
Ensure only Covaxin is given to 15-18 group: Bharat Biotech
Hyderabad: Bharat Biotech has urged healthcare workers to ensure that only Covaxin is administered to individuals in the 15-18 years age group. The Hyderabad-based vaccine maker on Tuesday said that it “received…
- India
DCGI to review applications of Bharat Biotech, SII for full market approval to Covaxin, Covishield today
New Delhi: Drugs Controller General of India (DCGI)’s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively…
- Andhra Pradesh
Bharat Biotech donates Rs two crore to TTD-run trust
Tirupati: The chairman and managing director of Bharat Biotech International Limited Krishna Ella on Thursday made an offering of Rs two crore at the hill shrine of Lord Venkateswara at nearby Tirumala…
- India
Covaxin booster can neutralise Omicron: Bharat Biotech
New Delhi: Covaxin’s booster dose is able to neutralise the vaccine evading Omicron variant of Covid-19, according to a study conducted at US’ Emory University, Bharat Biotech announced on Wednesday. Earlier studies…
- Hyderabad
Administer only Covaxin to 15-18 age group: Bharat Biotech to healthcare workers
Hyderabad: Hyderabad-based vaccine manufacturer Bharat Biotech on Friday said that it has received reports of COVID-19 vaccines other than Covaxin are being administered in children of age group 15-18 years in the…
- India
DGCI approves for phase III trial of Bharat Biotech intranasal vaccine as booster
New Delhi: The Subject Experts Committee (SEC) of the Drug Controller General of India (DGCI) on Wednesday granted “in principle” approval to Bharat Biotech to conduct “Phase III superiority study and Phase…
